130 related articles for article (PubMed ID: 38741391)
1. Remission of chronic urticaria in patients treated with omalizumab.
Cvenkel K; Bizjak M; Šelb J; Košnik M
Acta Dermatovenerol Alp Pannonica Adriat; 2024 Jun; 33(2):59-61. PubMed ID: 38741391
[TBL] [Abstract][Full Text] [Related]
2. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment.
Türk M; Yılmaz İ; Nazik Bahçecioğlu S; Can P; Ertaş R; Kartal D; Çınar SL; Kocatürk E
Dermatol Ther; 2021 Jan; 34(1):e14543. PubMed ID: 33190334
[TBL] [Abstract][Full Text] [Related]
5. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
6. Long-term management of chronic spontaneous urticaria with omalizumab.
Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
[TBL] [Abstract][Full Text] [Related]
7. Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data.
Salman A; Aktas M; Apti Sengun O
Australas J Dermatol; 2021 Aug; 62(3):398-402. PubMed ID: 34156714
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM
Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
[TBL] [Abstract][Full Text] [Related]
11. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
Zubiaga-Fernandez L; Testera-Montes A; Rondon C; Perez-Sanchez N; Gomez-Perez F; Vega-Chicote JM; Bartra J; Ferrer M; Eguiluz-Gracia I; Torres MJ
Clin Exp Allergy; 2024 Jun; 54(6):402-411. PubMed ID: 38343206
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment.
Cubiró X; Spertino J; Rozas-Muñoz E; Serra-Baldrich E; Puig L
Actas Dermosifiliogr (Engl Ed); 2019 May; 110(4):289-296. PubMed ID: 30360885
[TBL] [Abstract][Full Text] [Related]
16. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
18. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
19. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria.
Ayse Ornek S; Orcen C; Church MK; Kocaturk E
Int Immunopharmacol; 2022 Nov; 112():109198. PubMed ID: 36115277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
